AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.
You may also be interested in...
Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron
AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.
Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron
AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.
AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City